Neuropathic pain and use of PainDETECT in patients with fibromyalgia: a cohort study
© Gauffin et al.; licensee BioMed Central Ltd. 2013
Received: 14 August 2012
Accepted: 8 February 2013
Published: 14 February 2013
Skip to main content
© Gauffin et al.; licensee BioMed Central Ltd. 2013
Received: 14 August 2012
Accepted: 8 February 2013
Published: 14 February 2013
Fibromyalgia has a plethorae of symptoms, which can be confusing and even misleading. Accurate evaluation is necessary when patients with fibromyalgia are treated. Different types of instruments are available for the clinicians to supplement evaluation. Our objective was to study the applicability of the PainDETECT instrument to screen neuropathic pain in patients with fibromyalgia.
158 patients with primary fibromyalgia underwent a neurological examination including bedside sensory testing. They also fulfilled four questionnaires: PainDETECT, Beck depression inventory IA (BDI IA), Fibromyalgia Impact Questionnaire (FIQ) and a self-made questionnaire regarding present pain and pain relieving methods of the patients. The results of the clinical evaluation and questionnaires were then compared.
Clinically verified neuropathic pain was diagnosed in 53/158 [34% (95% Cl: 26 to 41)] patients. The ROC curve achieved a maximum Youden´s index at score of 17 when sensitivity was 0.79 (95% Cl: 0.66 to 0.89) and specificity 0.53 (95% Cl: 0.43 to 0.63). The PainDETECT total score (OR: 1.14 95% Cl: 1.06 to 1.22), FM as the worst current pain (OR: 0.31; 95% 0.16 to 0.62), body mass index (BMI) (OR: 1.05; 95% Cl: 1.00 to 1.11) and the intensity of current pain (OR: 1.20; 95% Cl: 1.01 to 1.41) were significantly associated with the presence of neuropathic pain in univariate analyses.
This study highlights the importance of thorough clinical examination. The Neuropathic pain screening tool PainDETECT is not as useful in patients with fibromyalgia as in patients with uncompromised central pain control.
Fibromyalgia (FM) is a chronic pain syndrome, which affects up to 5% of the general population . Characteristic features of FM are widespread musculoskeletal pain and tenderness as well as fatigue in the absence of any explanatory organic disease . Other usual symptoms are disturbed sleep, cognitive problems and a variety of psychosomatic symptoms originating from various organs . Patients with FM often complain also about tingling, numbness, burning pain, cutaneous hyperalgesia, and pain attacks , which are typical symptoms of neuropathic pain. The IASP (International Association for Study of Pain) defined neuropathic pain recently as “pain caused by a lesion or disease of the somatosensory system” . The prevalence of neuropathic pain in the general population is poorly known. Two population-based studies from Europe reported the prevalence of pain predominantly of neuropathic origin  or pain with neuropathic characteristics  to be 8% and 7%, respectively when assessed with a screening questionnaire without clinical confirmation of the diagnosis. According to a population-based study, the prevalence of neuropathic pain is around 10% in citizens aged 30 years or older .
Neuropathic pain screening tools such as PainDETECT are recommended for identifying patients with suspected neuropathic pain, particularly when used by non-specialists [9, 10]. Baron et al.  also showed that PainDETECT is useful for identifying different sensory profiles of neuropathic pain when a neuropathic pain condition (e.g. diabetic neuropathy or postherpetic neuralgia) has already been diagnosed. PainDETECT, which was developed and validated in Germany, incorporates a self-report questionnaire with 9 items . There are 7 weighted sensory descriptor items and 2 items relating to the spatial (radiating) and temporal characteristics of the individual pain pattern. Its sensitivity and specificity compared to clinical diagnosis is 85% and 80%, respectively. PainDETECT was initially developed and validated in patients with back pain but has shown applicability also to patients with other types of neuropatic pain. When using PainDETECT for screening purposes Freynhagen et al.  found cut-off scores ≤ 12 (a neuropathic component is unlikely) and ≥ 19 (a neuropathic component is likely) to be most appropriate. PainDETECT has been translated into several languages, including Finnish.
In this study we report the applicability of the PainDETECT tool to screen neuropathic pain in patients with fibromyalgia (FM).
Participants for the study were recruited from the patients with FM who had been diagnosed and treated in outpatient departments of Rheumatology or Physical medicine and rehabilitation of Jyväskylä Central Hospital between 2006 and 2008. Patients were identified using the ICD-10 code M79.0 according to the 2006 version. Based on medical records, patients with previously diagnosed neuropathic pain or neuropathy, active inflammatory arthritis, systemic connective tissue disease, cognitive impairment, severe psychiatric disorders (e.g., psychotic disorder, major depression, or severe anxiety disorder diagnosed by a psychiatrist) or any other unstable disease (e.g., cancer) were excluded. Only patients aged 18–65 years were included.
The questionnaires and consent form were sent to all traceable patients. The patients were asked to fill in four questionnaires: (1) PainDETECT, (2) Beck depression inventory IA (BDI IA) , (3) Fibromyalgia Impact Questionnaire (FIQ) , and (4) a one-page self-made questionnaire. Beck depression inventory IA is a 21-item questionnaire to assess possible depression and it is validated in Finnish . FIQ is a multidimensional self-administered questionnaire including 10 questions, which evaluate physical functioning, work status, depression, anxiety, sleep, pain, stiffness, fatigue and well-being. It is also validated in Finnish . The self-made questionnaire included questions regarding the pain condition of the patients, the intensity of their current pain, the effect of their pain relief methods, and the rank of FM pain compared to other possible pains.
Those who replied were invited to a clinical visit, where an experienced physician (TH) examined the patients and confirmed the diagnosis of FM according to the criteria of the American College of Rheumatology . Based on careful clinical history and physical examination, including neurological examination with meticulous bedside sensory testing, she also assessed whether the patient had neuropathic pain or not . The level of certainty of the neuropathic pain diagnosis was graded as definite, probable or possible . The grading system has four items: 1. Pain with a distinct neuroanatomically plausible distribution. 2. History suggestive of a relevant lesion or disease affecting the peripheral or central somatosensory system. 3. Demonstration of the distinct neuroanatomically plausible distribution by at least one test. And 4. Demonstration of the relevant lesion or disease by at least one test. The definite grade requires all items 1. to 4. The probable grade requires items 1. and 2. plus either 3. or 4. The possible grade requires items 1. and 2.
Results were expressed as means with standard deviation (SD) and 95% confidence intervals (CIs), and as medians with interquartile range (IQR). Statistical comparison between the groups was performed by t-test, permutation test or Chi-square test, when appropriate. Relationships between neuropathic pain and important risk factors were analyzed with univariate and multivariate forward stepwise logistic regression models. Receiver operating characteristic (ROC) curve was constructed to determine the cut-off point of PainDETECT that corresponds to the clinically verified neuropathic pain, with bias corrected bootstrap CIs. Values for the area under the ROC curve from 0.7 to 0.8 indicate reasonable discrimination and values exceeding 0.8 indicate good discrimination. We defined the best cut-off value as the value with the highest accuracy that maximizes the Youden's index. Sensitivity, specificity, positive predictive value, likelihood ratio, Youden's index, and their 95% CI values were calculated.
The study protocol was approved by The Committee of Research Ethics of Central Finland Health Care District, and the patients gave their informed consent in writing.
Demographic and clinical data of 158 FM patients with and without neuropathic pain diagnosis
NP N = 53
NNP N = 105
Females, number (%)
Age, mean (SD)
BMI, mean (SD)
Duration of diagnosis, median (IQR)
FIQ, mean (SD)
PainDETECT score, mean (SD)
Beck Depression Inventory, mean (SD)
Efficacy of pain relief*, mean (SD)
Health score**, mean (SD)
Current pain intensity***, mean (SD)
Number of patients with FM pain as their worst current pain (%)
Neuropathic pain diagnoses in 46 patients with probable or definite neuropathic pain
Probable NP N = 30
Definite NP N = 16
Method(s) of confirming definite NP diagnosis
ENMG (4), lumbar MRI (4)
ENMG (2), gene test* (1)
Peripheral nerve entrapment #
Peripheral nerve lesion ¤
Characteristics with 95 per cent confidence intervals of performance of different Pain DETECT cut-off scores
0.94 (0.84 to 0.99)
0.79 (0.43 to 0.89)
0.58 (0.44 to 0.72)
0.29 (0.20 to 0.38)
0.53 (0.43 to 0.63)
0.67 (0.57 to 0.76)
Predictive value of positive test
0.40 (0.31 to 0.49)
0.46 (0.36 to 0.57)
0.47 (0.35 to 0.60
Likelihood ratio (positive)
1.32 (1.14 to 1.53)
1.70 (1.33 to 2.17)
1.75 (1.23 to 2.50)
0.23 (0.13 to 0.33)
0.33 (0.17 to 0.47)
0.25 (0.08 to 0.41)
Logistic regression models for the odds to presence of neuropathic pain in FM patients
Univariate OR (95% CI)
Multivariate* OR (95% CI)
0.61 (0.16 to 2.38)
1.03 (1.00 to 1.07)
Body mass index
1.05 (1.00 to 1.11)
Duration of fibromyalgia diagnosis
1.02 (.96 to 1.08)
1.12 (.94 to 1.33)
PainDETECT total score
1.14 (1.06 to 1.22)
1.16 (1.08 to 1.25)
Beck Depression Inventory
1.01 (.97 to 1.05)
Efficacy of pain relief
0.86 (.71 to 1.04)
0.99 (.84 to 1.17)
Current pain intensity
1.20 (1.01 to 1.41)
FM pain as the worst current pain
0.31 (.16 to .62)
0.25 (0.11 to 0.53)
1.00 (1.00 to 1.00)
Our main finding showed that PainDETECT cannot distinguish neuropathic pain from non-neuropathic pain in FM patients. In the PainDETECT validation study a cut-off value of 19 points had both sensitivity and specificity of 0.84 , whereas that cut-off value reached sensitivity of 0.59 and specificity of 0.67 in our cohort. In our study the optimal cut-off value was 17 points with sensitivity of 0.79 and a low specificity of 0.53. The PainDETECT score and FM as the worst current pain had the strongest association with the presence of neuropathic pain, the latter having negative association, i.e., FM pain as the worst current pain proved to be a protective marker to neuropathic pain. Based on these results of sensitivity and specificity we do not recommend the use of PainDETECT for patients with FM as the principal diagnostic tool. It is worth noting that FM patients were excluded from the validation studies of PainDETECT and DN4 (another neuropathic pain screening tool) . Likewise patients with “mixed pain” were excluded from the validation study of LANSS . A recent review recommended that neuropathic pain screening tools should not be used for patients with widespread pain . Although neuropathic pain screening tools have not been validated with FM patients, Rhem et al.  and Koroschetz et al.  used PainDETECT to classify FM patients on the basis of their sensory symptoms. On the basis of LANSS results in FM patients Martinez-Lavin et al.  even suggested that FM might be a neuropathic pain state.
Although patients with previously diagnosed neuropathic pain were excluded, and therefore the prevalence of neuropathic pain was underestimated in our study, neuropathic pain was found in 37% of the patients. This is about five-fold compared to the prevalence in the general population according to the studies using LANSS  and DN4 .
It is important to bear the possibility of neuropathic pain in mind when a FM patient complains of sensory symptoms and pain with neuroanatomically plausible distribution. In such cases, careful examination of the patient is needed to support or exclude the diagnosis of neuropathic pain; FM and neuropathic pain are not mutually exclusive. Depending of the location of the pain and findings in the bedside examination, additional test (e.g., electroneuromyography in suspected peripheral nerve lesion, quantitative sensory testing and skin biopsy in suspected small fiber neuropathy, or magnetic resonance imaging in suspected central nervous system lesion) may be indicated (see more detailed report in [10, 18]).
It is generally assumed that the bodily distress disorders are highly associated with emotional distress, e.g., mood disorder. However, according to the BDI results, our patients with and without neuropathic pain had similar level of depressive symptoms.
The limitations of our study are retrospective setting, cross-sectional clinical evaluation, descriptive nature of the study (we were not allowed to perform additional diagnostic procedures to improve the level of certainty of the neuropathic pain diagnosis), secondary health care setting, and ignorance of other pains but FM and neuropathic pain.
Diagnosis of neuropathic pain may give an opportunity for curative treatment of the cause of neuropathic pain (e.g., surgical release of a nerve entrapment). In addition, patients with both FM and neuropathic pain might be favorable candidates for a treatment trial with tricyclic antidepressants, pregabalin or duloxetine, which have proved their efficacy for both conditions [25–27].
This study highlights the importance of thorough clinical examination when a FM patient emerges with new symptoms. Neuropathic pain screening tools such as PainDETECT are not as useful for FM patients as for other patient. However, if it is used, a positive PainDETECT score still attracts the clinician’s attention to the possibility of neuropathic pain and encourages performing an adequate neurological examination and the consideration of further testing when needed.
The study received financial support from the research funds of Rehabilitation Orton and the Social Insurance Institute of Finland. We appreciate their support for this study.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.